1. Home
  2. INCR vs INKT Comparison

INCR vs INKT Comparison

Compare INCR & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intercure Ltd.

INCR

Intercure Ltd.

HOLD

Current Price

$0.77

Market Cap

50.4M

Sector

Health Care

ML Signal

HOLD

Logo MiNK Therapeutics Inc.

INKT

MiNK Therapeutics Inc.

HOLD

Current Price

$9.39

Market Cap

57.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INCR
INKT
Founded
1994
2017
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.4M
57.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
INCR
INKT
Price
$0.77
$9.39
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$35.00
AVG Volume (30 Days)
47.3K
149.8K
Earning Date
03-30-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$69.54
N/A
Revenue Next Year
$41.75
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$6.66
52 Week High
$1.77
$76.00

Technical Indicators

Market Signals
Indicator
INCR
INKT
Relative Strength Index (RSI) 32.81 40.89
Support Level $0.68 $6.80
Resistance Level $0.88 $12.64
Average True Range (ATR) 0.03 0.73
MACD -0.00 -0.13
Stochastic Oscillator 24.29 8.37

Price Performance

Historical Comparison
INCR
INKT

About INCR Intercure Ltd.

Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

Share on Social Networks: